Response of Scalp and Skull Metastasis to Anti-PD-1 Antibody Combined with Regorafenib Treatment in a Sorafenib-Resistant Hepatocellular Carcinoma Patient and a Literature Review.

Xin Long Lei ZhangWen-Qiang WangEr-Lei ZhangXing LvZhi-Yong Huang

Published in: OncoTargets and therapy (2022)

Sorafenib-regorafenib sequential treatment combined with sintilimab is safe and effective when used to treat HCC skull metastasis, for which high-level evidence is needed to support this treatment strategy.

Keyphrases

replacement therapy